The stock price of Verrica Pharmaceuticals Inc (NASDAQ: VRCA) has jumped by 17.45% compared to previous close of $0.71. Despite this, the company has seen a gain of 58.82% in its stock price over the last five trading days. globenewswire.com reported 2025-07-01 that – Verrica to receive a $8 million milestone payment for initiation of the global study in July 2025, ahead of previous schedule –
Is It Worth Investing in Verrica Pharmaceuticals Inc (NASDAQ: VRCA) Right Now?
Moreover, the 36-month beta value for VRCA is 1.92. Analysts have varying opinions on the stock, with 2 analysts rating it as a “buy”, 0 as “overweight”, 2 as “hold”, and 0 as “sell”.
The public float for VRCA is 50.08M and currently, short sellers hold a 5.93% of that float. On July 08, 2025, VRCA’s average trading volume was 422.79K shares.
VRCA’s Market Performance
The stock of Verrica Pharmaceuticals Inc (VRCA) has seen a 58.82% increase in the past week, with a 39.52% rise in the past month, and a 97.62% gain in the past quarter. The volatility ratio for the week is 15.08%, and the volatility levels for the past 30 days are at 11.57% for VRCA. The simple moving average for the past 20 days is 33.71% for VRCA’s stock, with a 2.06% simple moving average for the past 200 days.
Analysts’ Opinion of VRCA
Jefferies gave a rating of “Buy” to VRCA, setting the target price at $10 in the report published on March 22nd of the previous year.
VRCA Trading at 46.58% from the 50-Day Moving Average
After a stumble in the market that brought VRCA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -90.76% of loss for the given period.
Volatility was left at 11.57%, however, over the last 30 days, the volatility rate increased by 15.08%, as shares surge +42.25% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +80.95% upper at present.
During the last 5 trading sessions, VRCA rose by +58.82%, which changed the moving average for the period of 200-days by -56.08% in comparison to the 20-day moving average, which settled at $0.6207. In addition, Verrica Pharmaceuticals Inc saw -88.89% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at VRCA starting from Hayes Christopher G., who sold 4,315 shares at the price of $0.65 back on Mar 17 ’25. After this action, Hayes Christopher G. now owns 176,458 shares of Verrica Pharmaceuticals Inc, valued at $2,805 using the latest closing price.
Hayes Christopher G., the CHIEF LEGAL OFFICER of Verrica Pharmaceuticals Inc, sale 26,183 shares at $2.66 during a trade that took place back on Aug 26 ’24, which means that Hayes Christopher G. is holding 115,303 shares at $69,647 based on the most recent closing price.
Stock Fundamentals for VRCA
Current profitability levels for the company are sitting at:
- -7.72% for the present operating margin
- 0.72% for the gross margin
The net margin for Verrica Pharmaceuticals Inc stands at -9.19%. The total capital return value is set at -4.34%. Equity return is now at value -1546.58%, with -121.65% for asset returns.
Based on Verrica Pharmaceuticals Inc (VRCA), the company’s capital structure generated -3.7 points at debt to capital in total, while cash flow to debt ratio is standing at -3.67. The debt to equity ratio resting at -0.79. The interest coverage ratio of the stock is -11.34.
Currently, EBITDA for the company is -65.9 million with net debt to EBITDA at 0.27. When we switch over and look at the enterprise to sales, we see a ratio of 8.61. The receivables turnover for the company is 1.28for trailing twelve months and the total asset turnover is 0.17. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.34.
Conclusion
To wrap up, the performance of Verrica Pharmaceuticals Inc (VRCA) has been better in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
